Custom Search

FDA Information

Ziprasidone was the fifth atypical antipsychotic to gain FDA approval.

Oral Geodon® received U.S. Food and Drug Administration approval for use in the treatment of schizophrenia in February 2001. It is also approved in more than 30 countries worldwide.

On the other hand, Geodon® for injection was the first atypical antipsychotic medicine approved in the United States, in 2002, for intramuscular (IM) use.

Ziprasidone is FDA-approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. It has also received approval for acute treatment of mania associated with bipolar disorder.

Please visit the official site of the FDA for further information.


Why is this medication prescribed?

Other uses for this medicine

Dosage and using this medicine

What special precautions should I follow?

What should I do if I forget a dose?

What side effects can this medication cause?

What storage conditions are needed for this medicine?

In case of an emergency/overdose


Use of this site is subject to the following terms of use